SCYX
SCYNEXIS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.46
+0.22%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.72
- Revenue estimate
- $147.0K
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- $0.63
- EPS estimate
- -$0.51
- Revenue actual
- $235.0K
- Revenue estimate
- $80.3K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -22.6%
- Revenue beats (12Q)
- 6
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.51 | $0.63 | Beat 224.34% | $235.0K |
| May 11, 2026 | -$0.10 | -$0.42 | Miss -320.00% | — |
| Mar 4, 2026 | $0.29 | $0.25 | Miss -13.79% | $18.6M |
| Nov 5, 2025 | -$0.21 | -$0.17 | Beat 19.05% | $334.0K |
| Aug 13, 2025 | -$0.23 | -$0.14 | Beat 39.13% | $1.4M |
| May 15, 2025 | -$0.23 | -$0.17 | Beat 26.09% | $257.0K |
| Mar 12, 2025 | -$0.22 | -$0.09 | Beat 59.09% | $977.0K |
| Aug 8, 2024 | -$0.19 | -$0.30 | Miss -57.89% | $736.0K |
| Nov 13, 2023 | $0.29 | -$0.04 | Miss -113.79% | $1.8M |
| Aug 14, 2023 | $1.55 | $2.46 | Beat 58.71% | $131.5M |
| May 11, 2023 | -$0.28 | -$0.25 | Beat 10.71% | — |
| Mar 31, 2023 | -$0.50 | -$0.29 | Beat 42.00% | $1.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026